已收盤 11-20 16:00:00 美东时间
-0.750
-0.50%
AI is starting to reshape how big pharma searches for the next blockbuster drug, and that shift is pulling fresh attention to a handful of companies that talk openly about using algorithms, machine learning and computational chemistry in their pipelines. If you care about where capital may cluster next, ignoring this theme risks missing a potential re-rating story. This article unpacks three AI-exposed giants from the screener and explains why th
11-20 22:09
Anthropic飙涨26%!最新总市值达1.37万亿美元,晋级史上规模最大IPO,亚马逊、谷歌、英伟达、微软均为公司大股东>>
11-20 01:00
An update from Novartis ( ($NVS) ) is now available. Novartis is a pure-play in...
11-19 22:38
Amneal Pharmaceuticals' biosimilar Adcomfo (omalizumab), developed as a biosimilar to XOLAIR, has received European Commission marketing authorization, following UK MHRA approval in March 2026. Adcomfo is approved for treating severe persistent allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticaria. Clinical studies demonstrated biosimilarity to the reference product, with comparable efficacy and safety. The ...
11-17 21:05
https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-cosentyx-adolescents-aged-12-hidradenitis-suppurativa-hs
11-14 02:48
Novartis ( ($NVS) ) has shared an update. On November 9, 2026, Novartis Capital...
11-13 06:16
Cardiff Oncology announced positive Phase 2 trial results for onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC), with median PFS not reached in the 30 mg onvansertib + FOLFIRI/bev arm versus 11 months in the control arm. All patients in the 30 mg arm have exceeded 21 months on treatment. The company plans to initiate a registrational Phase 3 trial in Q1 2027, targeting first-line RAS-mutated mCRC. Cardiff also reported $33...
11-12 12:00
11月7日,瑞士制药巨头诺华(Novartis)宣布,基本放弃旗下实验性心血管药物pelacarsen的开发,此前一项历时七年、涉及8322名患者的III期临床...
11-08 14:41